WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Winter sports become new custom of ChinaFiji pins growth hopes on Chinese tourists, plans direct flights from HKTourists from China and Kazakhstan to enjoy mutual visaRwanda basketball league resumes after 7A glimpse of the Beijing Olympic MuseumHarry Kane ends England's long wait for a final appearance to end Schmeichel's heroicsBeijing warming up for Winter GamesHighlights of women's artistic gymnastics qualification at Tokyo 2020 Olympic GamesKids' tour to Harbin becomes online hit1.334 bln people covered by China's basic medical insurance
2.4393s , 6515.984375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Investigation news portal